AstraZeneca: Diabetes Mellitus trials

The registry lists 122 Diabetes Mellitus studies with AstraZeneca as lead sponsor. 0 are open to participants now and 58 have results posted.

Phase 1 22Phase 2 16Phase 3 49Phase 4 6No phase 31(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)CompletedNCT00526552
• A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 DiabetesCompletedNCT00517283Phase 1
• Diabetic Under 70 (Diabetics Below 70)CompletedNCT00516204
• A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes MellitusCompletedNCT00477581Phase 4
• A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 DiabetesCompletedNCT00382239Phase 2
• Safety and Efficacy of Exenatide as MonotherapyCompletedNCT00381342Phase 3
• Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 DiabetesCompletedNCT00359879Phase 3
• Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and MetforminCompletedNCT00324363Phase 3
• The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy FemalesCompletedNCT00254800Phase 1
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes MellitusCompletedNCT00254254Phase 2
• Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 DiabetesCompletedNCT00241423Phase 2
• A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 DiabetesCompletedNCT00240253Phase 4
• Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 DiabetesCompletedNCT00111540Phase 3
• Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes MellitusCompletedNCT00108004Phase 3
• Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes MellitusCompletedNCT00107107Phase 3
• Study Examining Exenatide Long-Acting Release in Subjects With Type 2 DiabetesCompletedNCT00103935Phase 2
• Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate TherapyCompletedNCT00099619Phase 3
• Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic AgentsCompletedNCT00099333Phase 2
• Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and MetforminCompletedNCT00099320Phase 3
• Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes MellitusCompletedNCT00085969Phase 2
• Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I DiabetesCompletedNCT00064714Phase 2
• Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea CombinationCompletedNCT00044668Phase 3